Pancreatic β-Cell Response to Increased Metabolic Demand and to Pharmacologic Secretagogues Requires EPAC2A
(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.
EPAC2A ablation does not influence GSIS. A–D: In vivo studies. E and F: In vitro studies. EPAC2A KO mice and WT controls have similar glucose excursions during oGTT (A) and ipGTT (B). C: Serum insulin levels during ipGTT are not different in WT and EPAC2A KO mice. D: ipITT shows slightly increased insulin sensitivity in EPAC2A KO mice as compared with controls. E: WT and EPAC2A KO islets show similar insulin secretion rates during perifusion studies. F and G: Islet intracellular calcium dynamic changes detected with the Fura-2 method in EPAC2A KO and WT islets are similar. F: Islets maintained in 3 mmol/L glucose show no differences in intracellular calcium levels. G: Increasing glucose levels from 5 to 10 mmol/L at time 0 min elicits an increase in intracellular calcium signal, which is
similar in WT and EPAC2A KO islets. WT is represented in gray circles; EPAC2A KO is represented in black circles. Results
are shown as mean ± SEM of studies performed at least in triplicate. *P < 0.05.